Search

Your search keyword '"Lorusso, D"' showing total 1,421 results
Start Over Author "Lorusso, D"
1,421 results on '"Lorusso, D"'

1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Author

Monk, B.J., Barretina-Ginesta, M.P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M.R., McCormick, C.C., Lorusso, D., Moore, R.G., Freyer, G., O’Cearbhaill, R.E., Heitz, F., O’Malley, D.M., Redondo, A., Shahin, M.S., Vulsteke, C., Bradley, W.H., Haslund, C.A., Chase, D.M., Pisano, C., Holman, L.L., Pérez, M. J. Rubio, DiSilvestro, P., Gaba, L., Herzog, T.J., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I.A., and González-Martín, A.

Published
2024
Full Text
View/download PDF

2. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy

Author

Pignata, S., Califano, D., Lorusso, D., Arenare, L., Bartoletti, M., De Giorgi, U., Andreetta, C., Pisano, C., Scambia, G., Lombardi, D., Farolfi, A., Cinieri, S., Passarelli, A., Salutari, V., De Angelis, C., Mignogna, C., Priolo, D., Capoluongo, E.D., Tamberi, S., Scaglione, G.L., Arcangeli, V., De Cecio, R., Scognamiglio, G., Greco, F., Spina, A., Turinetto, M., Russo, D., Carbone, V., Casartelli, C., Schettino, C., and Perrone, F.

Published
2024
Full Text
View/download PDF

3. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data

Author

Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, Nero C, Ricci C, Perri MT, Giudice E, Lardino S, Berardi R, Scambia G, and Lorusso D

Subjects
cervical cancer, gynecological cancer, antibody–drug conjugate, tissue factor., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Veronica Agostinelli,1 Lucia Musacchio,2 Floriana Camarda,2 Vanda Salutari,2 Maria Vittoria Carbone,2 Viola Ghizzoni,2 Camilla Nero,2 Caterina Ricci,2 Maria Teresa Perri,2 Elena Giudice,3 Sara Lardino,3 Rossana Berardi,1 Giovanni Scambia,2,3 Domenica Lorusso2,3 1Oncologic Clinic, Università Politecnica delle Marche, Ancona, Italy; 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 3Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Vanda Salutari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, Roma, 00168, Italy, Tel +39-06-3015-3234, Email vanda.salutari@policlinicogemelli.itAbstract: Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with a high relapse risk and the second-line therapies are limited with modest response rates and short durability. Investigating alternative mechanisms of action is crucial because of the high request for effective new therapies. Tisotumab vedotin (TV) is the first antibody-drug conjugated to target a cell surface-expressed tissue factor, and preliminary data in patients with metastatic and recurrent cervical cancer have been promising. In addition, the trials showed a favorable tolerability profile, with limited incidence of grade 3 or worse adverse events. According to the data of ENGOT-cx6/GOG-3023/innovaTV 204, the US Food and Drug Administration granted expedited approval of TV on September 20, 2021, for women with recurrent or metastatic cervical cancer. Actually, two other trials testing TV alone or in combination with other agents are ongoing. ENGOT-cx8/GOG-3024/innovaTV 205 is a Phase Ib/II trial of TV in combination with platinum or bevacizumab or pembrolizumab, in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy or who have progressed after no more than two prior systemic therapies. ENGOT-cx12/GOG-3057/InnovaTV 301 is a Phase 3 trial of TV vs investigator’s choice chemotherapy in patients with advanced or recurrent cervical cancer who had received no more than 2 prior chemotherapy lines. The outcomes of these two trials will potentially confirm and reinforce the use of TV as a new standard of care in advanced or recurrent cervical cancer.Keywords: cervical cancer, gynecological cancer, antibody–drug conjugate, tissue factor

Published
2023

4. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J.A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A.G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., McCluggage, W.G., McNeish, I.A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J.A., Pignata, S., Ramirez, P.T., Ray-Coquard, I., Romero, I., Scambia, G., Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D.S.P., Taskiran, C., van Driel, W.J., Vergote, I., Planchamp, F., Sessa, C., and Fagotti, A.

Published
2024
Full Text
View/download PDF

8. Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention

Author

Falanga, A, Lorusso, D, Colombo, N, Cormio, G, Cosmi, B, Scandurra, G, Zanagnolo, V, Marietta, M, Falanga A., Lorusso D., Colombo N., Cormio G., Cosmi B., Scandurra G., Zanagnolo V., Marietta M., Falanga, A, Lorusso, D, Colombo, N, Cormio, G, Cosmi, B, Scandurra, G, Zanagnolo, V, Marietta, M, Falanga A., Lorusso D., Colombo N., Cormio G., Cosmi B., Scandurra G., Zanagnolo V., and Marietta M.

Abstract

The prevention and appropriate management of venous thromboembolism in cancer patients is of paramount importance. However, the literature data report an underestimation of this major problem in patients with gynecological cancers, with an inconsistent venous thromboembolism risk assessment and prophylaxis in this patient setting. This narrative review provides a comprehensive overview of the available evidence regarding the management of venous thromboembolism in cancer patients, focusing on the specific context of gynecological tumors, exploring the literature discussing risk factors, risk assessment, and pharmacological prophylaxis. We found that the current understanding and management of venous thromboembolism in gynecological malignancy is largely based on studies on solid cancers in general. Hence, further, larger, and well-designed research in this area is needed.

Published
2024

9. Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey

Author

Mongelli, M, Lorusso, D, Zanagnolo, V, Pignata, S, Colombo, N, Cormio, G, Mongelli M., Lorusso D., Zanagnolo V., Pignata S., Colombo N., Cormio G., Mongelli, M, Lorusso, D, Zanagnolo, V, Pignata, S, Colombo, N, Cormio, G, Mongelli M., Lorusso D., Zanagnolo V., Pignata S., Colombo N., and Cormio G.

Abstract

Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO (Mario Negri Gynecologic Oncology) groups. We designed a self-administered, multiple-choice online questionnaire available only for MITO-MaNGO members for one month, starting in May 2022 and ending in June 2022. We processed one response form per center, and 50 responses were analyzed, with most of the respondents (78%) over 40 years old. We found that 82% of them consider thromboembolic prophylaxis in gynecologic oncology to be relevant. In 82% of the centers, a standardized protocol on venous thromboembolism (VTE) prophylaxis is used, which is applied to both patients undergoing surgery and those undergoing chemotherapy. In the remaining 18% of centers, prophylaxis is used exclusively for patients undergoing chemotherapy treatment. Prophylaxis of patients undergoing surgery and chemotherapy treatment is managed in most cases by the surgeon (72%) and oncologist (76%), respectively. Only 26% of respondents use a thromboembolic risk assessment scale, and of these, those used are the Caprini Score (6%), Khorana Score (6%), and Wells Score (2%). The respondents have good knowledge of low-molecular-weight heparin (90%) and average knowledge of dicumarolics (40%), direct oral anticoagulants (DOACs) (68%), and antiplatelet agents (40%). The results of our survey indicate that there is a good awareness of thromboembolic prophylaxis in gynecologic oncology. Nevertheless, it is used less in outpatients than in patients undergoing surgery. Moreover, the thromboembolic risk assessment scores are barely used.

Published
2024

10. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J, Matias-Guiu, X, Amant, F, Concin, N, Davidson, B, Fotopoulou, C, González-Martin, A, Gourley, C, Leary, A, Lorusso, D, Banerjee, S, Chiva, L, Cibula, D, Colombo, N, Croce, S, Eriksson, A, Falandry, C, Fischerova, D, Harter, P, Joly, F, Lazaro, C, Lok, C, Mahner, S, Marmé, F, Marth, C, Mccluggage, W, Mcneish, I, Morice, P, Nicum, S, Oaknin, A, Pérez-Fidalgo, J, Pignata, S, Ramirez, P, Ray-Coquard, I, Romero, I, Scambia, G, Sehouli, J, Shapira-Frommer, R, Sundar, S, Tan, D, Taskiran, C, van Driel, W, Vergote, I, Planchamp, F, Sessa, C, Fagotti, A, Ledermann J. A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., Banerjee S., Chiva L., Cibula D., Colombo N., Croce S., Eriksson A. G., Falandry C., Fischerova D., Harter P., Joly F., Lazaro C., Lok C., Mahner S., Marmé F., Marth C., McCluggage W. G., McNeish I. A., Morice P., Nicum S., Oaknin A., Pérez-Fidalgo J. A., Pignata S., Ramirez P. T., Ray-Coquard I., Romero I., Scambia G., Sehouli J., Shapira-Frommer R., Sundar S., Tan D. S. P., Taskiran C., van Driel W. J., Vergote I., Planchamp F., Sessa C., Fagotti A., Ledermann, J, Matias-Guiu, X, Amant, F, Concin, N, Davidson, B, Fotopoulou, C, González-Martin, A, Gourley, C, Leary, A, Lorusso, D, Banerjee, S, Chiva, L, Cibula, D, Colombo, N, Croce, S, Eriksson, A, Falandry, C, Fischerova, D, Harter, P, Joly, F, Lazaro, C, Lok, C, Mahner, S, Marmé, F, Marth, C, Mccluggage, W, Mcneish, I, Morice, P, Nicum, S, Oaknin, A, Pérez-Fidalgo, J, Pignata, S, Ramirez, P, Ray-Coquard, I, Romero, I, Scambia, G, Sehouli, J, Shapira-Frommer, R, Sundar, S, Tan, D, Taskiran, C, van Driel, W, Vergote, I, Planchamp, F, Sessa, C, Fagotti, A, Ledermann J. A., Matias-Guiu X., Amant F., Concin N., Davidson B., Fotopoulou C., González-Martin A., Gourley C., Leary A., Lorusso D., Banerjee S., Chiva L., Cibula D., Colombo N., Croce S., Eriksson A. G., Falandry C., Fischerova D., Harter P., Joly F., Lazaro C., Lok C., Mahner S., Marmé F., Marth C., McCluggage W. G., McNeish I. A., Morice P., Nicum S., Oaknin A., Pérez-Fidalgo J. A., Pignata S., Ramirez P. T., Ray-Coquard I., Romero I., Scambia G., Sehouli J., Shapira-Frommer R., Sundar S., Tan D. S. P., Taskiran C., van Driel W. J., Vergote I., Planchamp F., Sessa C., and Fagotti A.

Abstract

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

Published
2024

11. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)

Author

Salani, R, Mccormack, M, Kim, Y, Ghamande, S, Hall, S, Lorusso, D, Barraclough, L, Gilbert, L, Guzman Ramirez, A, Lu, C, Sabatier, R, Colombo, N, Hu, Y, Krishnan, V, Molinero, L, Feng, Y, Kim, N, Castro, M, Lin, Y, Monk, B, Salani R., McCormack M., Kim Y. -M., Ghamande S., Hall S. L., Lorusso D., Barraclough L., Gilbert L., Guzman Ramirez A., Lu C. -H., Sabatier R., Colombo N., Hu Y., Krishnan V., Molinero L., Feng Y., Kim N., Castro M., Lin Y. G., Monk B. J., Salani, R, Mccormack, M, Kim, Y, Ghamande, S, Hall, S, Lorusso, D, Barraclough, L, Gilbert, L, Guzman Ramirez, A, Lu, C, Sabatier, R, Colombo, N, Hu, Y, Krishnan, V, Molinero, L, Feng, Y, Kim, N, Castro, M, Lin, Y, Monk, B, Salani R., McCormack M., Kim Y. -M., Ghamande S., Hall S. L., Lorusso D., Barraclough L., Gilbert L., Guzman Ramirez A., Lu C. -H., Sabatier R., Colombo N., Hu Y., Krishnan V., Molinero L., Feng Y., Kim N., Castro M., Lin Y. G., and Monk B. J.

Abstract

Objective: To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer. Methods: In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients with PD-L1-positive (SP263 tumor area positivity ≥5%) recurrent/persistent cervical cancer after 1-2 chemotherapy lines (≥1 platinum-based) were randomized 3:1 to atezolizumab 1200 mg with/without tiragolumab 600 mg every 3 weeks until disease progression or unacceptable toxicity. Stratification factors were performance status, prior (chemo)radiotherapy, and disease status. The primary endpoint was independent review committee-assessed confirmed objective response rate per RECIST v1.1 in patients receiving tiragolumab plus atezolizumab. An objective response rate ≥21% (one-sample z-test p≤0.0245) was required for statistical significance versus a historical reference. Results: Protocol-defined independent review committee-assessed objective response rates were 19.0% (95% CI 12.6 to 27.0) in 126 patients receiving tiragolumab plus atezolizumab (p=0.0787 vs historical reference) and 15.6% (95% CI 6.5 to 29.5) in 45 atezolizumab-treated patients. Response rates were higher in PD-L1high (tumor area positivity ≥10%) than PD-L1low (tumor area positivity 5%-9%) subgroups with both regimens. At 8.5 months' median follow-up, independent review committee-assessed progression-free survival was 2.8 months (95% CI 1.7 to 4.1) with tiragolumab plus atezolizumab and 1.9 months (95% CI 1.5 to 3.0) with atezolizumab. In post hoc analyses (10.4 months' median follow-up), median overall survival was 11.1 months (95% CI 9.6 to 14.5) with the combination and 10.6 months (95% CI 6.9 to 13.8) with atezolizumab (crossover permitted). In the combination group, 3% of patients had adverse events requiring treatment discontinuation and 8% had grade ≥3 adverse events of special interest; corresponding values in the single

Published
2024

12. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

Author

Lorusso, D, Raspagliesi, F, Ronzulli, D, Valabrega, G, Colombo, N, Pisano, C, Cassani, C, Tognon, G, Tamberi, S, Mangili, G, Mammoliti, S, De Giorgi, U, Greco, F, Mosconi, A, Breda, E, Artioli, G, Andreetta, C, Casanova, C, Ceccherini, R, Frassoldati, A, Salutari, V, Giolitto, S, Scambia, G, Lorusso D., Raspagliesi F., Ronzulli D., Valabrega G., Colombo N., Pisano C., Cassani C., Tognon G., Tamberi S., Mangili G., Mammoliti S., De Giorgi U., Greco F., Mosconi A. M., Breda E., Artioli G., Andreetta C., Casanova C., Ceccherini R., Frassoldati A., Salutari V., Giolitto S., Scambia G., Lorusso, D, Raspagliesi, F, Ronzulli, D, Valabrega, G, Colombo, N, Pisano, C, Cassani, C, Tognon, G, Tamberi, S, Mangili, G, Mammoliti, S, De Giorgi, U, Greco, F, Mosconi, A, Breda, E, Artioli, G, Andreetta, C, Casanova, C, Ceccherini, R, Frassoldati, A, Salutari, V, Giolitto, S, Scambia, G, Lorusso D., Raspagliesi F., Ronzulli D., Valabrega G., Colombo N., Pisano C., Cassani C., Tognon G., Tamberi S., Mangili G., Mammoliti S., De Giorgi U., Greco F., Mosconi A. M., Breda E., Artioli G., Andreetta C., Casanova C., Ceccherini R., Frassoldati A., Salutari V., Giolitto S., and Scambia G.

Abstract

PURPOSELiterature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype.METHODSA prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin). The primary end point was overall survival (OS) evaluated in the intention-to-treat population.RESULTSOverall, 244 patients from 21 MITO centers were randomly assigned (arm A = 122/arm B = 122). More than 70% of patients received ≥three previous chemotherapy lines and 35.7% had received a poly (ADP-ribose) polymerase inhibitor (PARPi) before enrollment. Median OS was not significantly different between the arms: arm A: 15.8 versus arm B: 17.9 months (P =.304). Median progression-free survival was 4.9 months in arm A versus 4.4 months in arm B (P =.897). Among 208 patients evaluable for efficacy, the objective response rate was 17.1% in arm A and 21.4% in arm B, with comparable median duration of response (5.62 v 5.66 months, respectively). No superior effect was observed for trabectedin in the prespecified subgroup analyses according to BRCA mutational status, chemotherapy type, and pretreatment with a PARPi and/or platinum-free interval. Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions compared with control chemotherapy.CONCLUSIONTrabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.

Published
2024

13. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Author

Tewari, K, Colombo, N, Monk, B, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yanez, E, Gumus, M, de Mendoza, M, Samouelian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Toker, S, Keefe, S, Lorusso, D, Tewari K. S., Colombo N., Monk B. J., Dubot C., Caceres M. V., Hasegawa K., Shapira-Frommer R., Salman P., Yanez E., Gumus M., de Mendoza M. O. H., Samouelian V., Castonguay V., Arkhipov A., Tekin C., Li K., Toker S., Keefe S. M., Lorusso D., Tewari, K, Colombo, N, Monk, B, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yanez, E, Gumus, M, de Mendoza, M, Samouelian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Toker, S, Keefe, S, Lorusso, D, Tewari K. S., Colombo N., Monk B. J., Dubot C., Caceres M. V., Hasegawa K., Shapira-Frommer R., Salman P., Yanez E., Gumus M., de Mendoza M. O. H., Samouelian V., Castonguay V., Arkhipov A., Tekin C., Li K., Toker S., Keefe S. M., and Lorusso D.

Abstract

IMPORTANCE The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown. OBJECTIVE To assess efficacy outcomes in patient subgroups of KEYNOTE-826. DESIGN, SETTING, AND PARTICIPANTS Exploratory subgroup analyses were conducted in a global, phase 3, randomized, double-blind, placebo-controlled clinical trial. Participants included women with persistent, recurrent, or metastatic adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma of the cervix that had not been treated with systemic chemotherapy and was not amenable to curative treatment. This subanalysis was conducted from November 20, 2018, to May 3, 2021. INTERVENTIONS Pembrolizumab, 200 mg, every 3 weeks or placebo for up to 35 cycles plus chemotherapy (paclitaxel, 175 mg/m2, plus cisplatin, 50 mg/m2, or carboplatin AUC 5 [area under the free carboplatin plasma concentration vs time curve]) with or without bevacizumab, 15 mg/kg. MAIN OUTCOMES AND MEASURES Overall survival (OS) and progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 in subgroups defined by use of bevacizumab (yes or no), choice of platinum (carboplatin or cisplatin), prior chemoradiotherapy (CRT) exposure only (yes or no), and histologic type (squamous or nonsquamous) in patients with programmed cell death ligand 1-positive tumors (defined as a combined positive score [CPS] ≥1) and in the intention-to-treat population. RESULTS A total of 617 patients (median age, 51 years; range, 22-82 years) were enrolled in the trial. In the CPS greater than or equal to 1 population, hazard ratios (HRs) for OS favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.62; 95% CI, 0.45-0.8

Published
2024

14. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Author

Koppikar, S., Oaknin, A., Babu, K. Govind, Lorusso, D., Gupta, S., Wu, L.-Y., Rajabto, W., Harano, K., Hong, S.-H., Malik, R.A., Strebel, H., Aggarwal, I.M., Lai, C.-H., Dejthevaporn, T., Tangjitgamol, S., Cheng, W.F., Chay, W.Y., Benavides, D., Hashim, N.M., Moon, Y.W., Yunokawa, M., Anggraeni, T.D., Wei, W., Curigliano, G., Maheshwari, A., Mahantshetty, U., Sheshadri, S., Peters, S., Yoshino, T., and Pentheroudakis, G.

Published
2023
Full Text
View/download PDF

15. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Author

Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., and Harter, P.

Published
2023
Full Text
View/download PDF

16. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

Author

Capoluongo, E.D., Pellegrino, B., Arenare, L., Califano, D., Scambia, G., Beltrame, L., Serra, V., Scaglione, G.L., Spina, A., Cecere, S.C., De Cecio, R., Normanno, N., Colombo, N., Lorusso, D., Russo, D., Nardelli, C., D’Incalci, M., Llop-Guevara, A., Pisano, C., Baldassarre, G., Mezzanzanica, D., Artioli, G., Setaro, M., Tasca, G., Roma, C., Campanini, N., Cinieri, S., Sergi, A., Musolino, A., Perrone, F., Chiodini, P., Marchini, S., and Pignata, S.

Published
2022
Full Text
View/download PDF

19. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Author

Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., and Garralda, E.

Published
2022
Full Text
View/download PDF

20. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Author

Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Bjorge, L., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., Davidson, B., de la Motte Rouge, T., De Iaco, P., Demirkiran, F., Denys, H., Doerk, T., Dorum, A., Ferrero, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Heinzelmann, V., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., López-Guerrero, J.A., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Ojamaa, K., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Sapino, A., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Van de Vijver, K., Vardar, M.A., Wasag, B., Wimberger, P., Witteveen, E., Brenton, J.D., and Ausems, M.G.E.M.

Published
2022
Full Text
View/download PDF

23. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, investigators, ARIEL3, Buck, M, Dean, A, Friedlander, ML, Goh, JC, Harnett, P, Kichenadasse, G, Scott, CL, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, AM, Plante, M, Provencher, D, Weberpals, JI, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, RF, Scambia, G, Tamberi, S, Zamagni, C, Fong, PC, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, EM, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, SN, Clamp, A, Drew, Y, Gabra, HG, Jackson, D, Ledermann, JA, McNeish, IA, Parkinson, C, and Powell, M

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Cancer, Genetics, Clinical Trials and Supportive Activities, Ovarian Cancer, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Aged, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Indoles, Internationality, Maintenance Chemotherapy, Middle Aged, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Risk Assessment, Survival Rate, Treatment Outcome, ARIEL3 investigators, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundRucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.MethodsIn this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.FindingsBetween April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4-22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4-6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16-0·34]; p

Published
2017

24. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Author

Pignata, S, Lorusso, D, Joly, F, Gallo, C, Colombo, N, Sessa, C, Bamias, A, Salutari, V, Selle, F, Frezzini, S, De Giorgi, U, Pautier, P, Bologna, A, Orditura, M, Dubot, C, Gadducci, A, Mammoliti, S, Ray-Coquard, I, Zafarana, E, Breda, E, Favier, L, Ardizzoia, A, Cinieri, S, Largillier, R, Sambataro, D, Guardiola, E, Lauria, R, Pisano, C, Raspagliesi, F, Scambia, G, Daniele, G, Perrone, F, Pignata, Sandro, Lorusso, Domenica, Joly, Florence, Gallo, Ciro, Colombo, Nicoletta, Sessa, Cristiana, Bamias, Aristotelis, Salutari, Vanda, Selle, Frédèric, Frezzini, Simona, De Giorgi, Ugo, Pautier, Patricia, Bologna, Alessandra, Orditura, Michele, Dubot, Coraline, Gadducci, Angiolo, Mammoliti, Serafina, Ray-Coquard, Isabelle, Zafarana, Elena, Breda, Enrico, Favier, Laure, Ardizzoia, Antonio, Cinieri, Saverio, Largillier, Rémy, Sambataro, Daniela, Guardiola, Emmanuel, Lauria, Rossella, Pisano, Carmela, Raspagliesi, Francesco, Scambia, Giovanni, Daniele, Gennaro, and Perrone, Francesco

Published
2021
Full Text
View/download PDF

25. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

Author

Olawaiye, AB, Kim, J-W, Bagameri, A, Bishop, E, Chudecka-Głaz, A, Devaux, A, Gladieff, L, Gordinier, ME, Korach, J, McCollum, ME, Mileshkin, L, Monk, BJ, Nicum, S, Nogueira-Rodrigues, A, Oaknin, A, O'Malley, DM, Orlando, M, Dreiling, L, Tudor, IC, Lorusso, D, Olawaiye, AB, Kim, J-W, Bagameri, A, Bishop, E, Chudecka-Głaz, A, Devaux, A, Gladieff, L, Gordinier, ME, Korach, J, McCollum, ME, Mileshkin, L, Monk, BJ, Nicum, S, Nogueira-Rodrigues, A, Oaknin, A, O'Malley, DM, Orlando, M, Dreiling, L, Tudor, IC, and Lorusso, D

Abstract

BACKGROUND: Ovarian cancer has the highest mortality among gynecologic cancers, primarily because it typically is diagnosed at a late stage and because of the development of chemoresistance in recurrent disease. Improving outcomes in women with platinum-resistant ovarian cancer is a substantial unmet need. Activation of the glucocorticoid receptor (GR) by cortisol has been shown to suppress the apoptotic pathways used by cytotoxic agents, limiting their efficacy. Selective GR modulation may be able to counteract cortisol's antiapoptotic effects, enhancing chemotherapy's efficacy. A previous phase 2 study has shown that adding intermittently dosed relacorilant, a selective GR modulator, to nab-paclitaxel improved outcomes, including progression-free survival (PFS) and overall survival (OS), with minimal added toxicity, in women with recurrent platinum-resistant ovarian cancer. The ROSELLA study aims to confirm and expand on these findings in a larger population. METHODS: ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study in women with recurrent, platinum-resistant, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. Eligible participants have received 1 to 3 lines of prior systemic anticancer therapy, including ≥1 prior line of platinum therapy and prior treatment with bevacizumab, with documented progressive disease or intolerance to the most recent therapy. There is no biomarker-based requirement for participant selection. Participants are randomized 1:1 to receive intermittently dosed relacorilant in combination with nab-paclitaxel or nab-paclitaxel monotherapy. The study's primary efficacy endpoint is PFS as assessed by blinded independent central review. Secondary efficacy endpoints include OS, investigator-assessed PFS, objective response rate, best overall response, duration of response, clinical benefit rate at 24 weeks, and cancer antigen 125 response. The study is also evaluating safety and patient

Published
2024

26. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab

Author

Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Slomovitz, Brian, Hasegawa, Kosei, Nogueira-Rodrigues, Angélica, Zale, Melissa, Okpara, Chinyere E, Barresi, Gianmaria, McKenzie, Jodi, Makker, Vicky, Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo, Nicoletta, Lorusso, Domenica, Monk, Bradley J, Slomovitz, Brian, Hasegawa, Kosei, Nogueira-Rodrigues, Angélica, Zale, Melissa, Okpara, Chinyere E, Barresi, Gianmaria, McKenzie, Jodi, and Makker, Vicky

Abstract

Background: Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following prior platinum-based therapy, in Study-309/KEYNOTE-775. The safety profile of the combination was generally consistent with that of each monotherapy drug and of the combination in patients with endometrial cancer and other solid tumors. Given the medical complexity of patients with aEC, this paper aims to characterize key adverse reactions (ARs) of the combination treatment and review management strategies, providing a guide for AR management to maximize anticancer benefits and minimize treatment discontinuation. Materials and Methods: In Study-309/KEYNOTE-775, patients received lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously every 3 weeks) or chemotherapy (doxorubicin or paclitaxel). The incidence and median time to the first onset of ARs, dose modifications, and concomitant medications are described. Key ARs characterized include hypothyroidism, hypertension, fatigue, diarrhea, musculoskeletal disorders, nausea, decreased appetite, vomiting, stomatitis, weight decreased, proteinuria, and palmar-plantar erythrodysesthesia syndrome. Results: As expected, the most common any-grade key ARs included: hypothyroidism, hypertension, fatigue, diarrhea, and musculoskeletal disorders. Grades 3-4 key ARs with incidence ≥10% included: hypertension, fatigue, and weight decreased. Key ARs first occurred within approximately 3 months of treatment initiation. AR management strategies consistent with the prescribing information and the study protocol are discussed. Conclusion: Successful AR management strategies for lenvatinib plus pembrolizumab include education of the patient and entire treatment team, preventative measures and close monitoring, and judicious use of dose modifications and conco

Published
2024

27. Reply to P.-H. Luo et al

Author

Monk, B, Colombo, N, Tewari, K, Tekin, C, Keefe, S, Lorusso, D, Monk, BJ, Tewari, KS, Keefe, SM, Monk, B, Colombo, N, Tewari, K, Tekin, C, Keefe, S, Lorusso, D, Monk, BJ, Tewari, KS, and Keefe, SM

Published
2024

28. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Abstract

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient

Published
2024

29. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere

Author

Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), Fanfani F. (ORCID:0000-0003-1991-7284), Bruchim, I., Capasso, Ilaria, Polonsky, A., Meisel, S., Salutari, V., Werner, H., Lorusso, D., Scambia, Giovanni, Fanfani, Francesco, Capasso I., Scambia G. (ORCID:0000-0003-2758-1063), and Fanfani F. (ORCID:0000-0003-1991-7284)

Abstract

Introduction: Endometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision medicine with tailored therapy has revolutionized the management of this disease. Genome sequencing analyses have identified four sub-types of EC. Treatments for primary and metastatic disease can now be tailored more accurately to achieve better oncologic results. Areas covered: This review provides an overview of the most relevant and updated evidence in the literature regarding EC molecular analysis and its role in risk classification, prognostication, and guidance for tailored and target therapies in early and advanced/metastatic stages. In addition, it provides updated information on optimal surgical management based on molecular classification and highlights key advances and future strategies. Expert opinion: EC molecular analysis yields the potential of tailoring adjuvant treatment by escalating or deescalating therapy, as shown for POLE-mutated and p53-mutated tumors. Moreover, the expression of specific molecular signatures offers the possibility to employ novel target therapies, such as immune-checkpoint inhibitors that have demonstrated a significant benefit on prognosis. New treatment guidelines are still being established, and ongoing studies are exploring the potential prognostic role of further sub-stratifications of the four molecular classes and treatment options.

Published
2024

30. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Author

Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), Fagotti, A. (ORCID:0000-0001-5579-335X), Ledermann, J. A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, Domenica, Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A. G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., Mccluggage, W. G., Mcneish, I. A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J. A., Pignata, S., Ramirez, P. T., Ray-Coquard, I., Romero, I., Scambia, Giovanni, Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D. S. P., Taskiran, C., van Driel, W. J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, Anna, Lorusso, D., Scambia, G. (ORCID:0000-0003-2758-1063), and Fagotti, A. (ORCID:0000-0001-5579-335X)

Abstract

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

Published
2024

31. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Author

Mirza, Mansoor R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I. Bover, Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A. Casado, Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., de Jong, F.A., Gupta, D., and Matulonis, U.A.

Published
2020
Full Text
View/download PDF

33. 102P A retrospective description of actionable mutations incidence within a comprehensive cancer genome profiling programme: Is less still more?

Author

Camarda, F., primary, Nero, C., additional, Giacomini, F., additional, Duranti, S., additional, Bria, E., additional, Salvatore, L., additional, Iacovelli, R., additional, Marino, I., additional, Minucci, A., additional, Giacò, L., additional, Pasciuto, T., additional, Giannarelli, D., additional, Fagotti, A., additional, Fanfani, F., additional, Zannoni, G.F., additional, Lorusso, D., additional, Tortora, G., additional, Normanno, N., additional, and Scambia, G., additional

Published
2024
Full Text
View/download PDF

34. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Author

Oaknin, A., primary, Gladieff, L., additional, Martinez-Garcia, J., additional, Villacampa, G., additional, Takekuma, M., additional, De Giorgi, U.F.F., additional, Lindemann, K., additional, Woelber, L., additional, Colombo, N., additional, Duska, L.R., additional, Leary, A., additional, Godoy Ortiz, A., additional, Nishio, S., additional, Angelergues, A., additional, Rubio Perez, M.J., additional, Fariñas Madrid, L., additional, Yamaguchi, S., additional, Lorusso, D., additional, D'Hondt, V., additional, and Randall, L., additional

Published
2023
Full Text
View/download PDF

37. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab (Interpretation In Rus.)

Author

Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo N., Lorusso D., Monk B. J., Slomovitz B., Hasegawa K., Nogueira-Rodrigues A., Zale M., Okpara C. E., Barresi G., McKenzie J., Makker V., Colombo, N, Lorusso, D, Monk, B, Slomovitz, B, Hasegawa, K, Nogueira-Rodrigues, A, Zale, M, Okpara, C, Barresi, G, Mckenzie, J, Makker, V, Colombo N., Lorusso D., Monk B. J., Slomovitz B., Hasegawa K., Nogueira-Rodrigues A., Zale M., Okpara C. E., Barresi G., McKenzie J., and Makker V.

Abstract

Background. Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endome-trial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following prior platinum-based therapy, in Study-309/KEYNOTE-775. The safety profile of the combination was generally consistent with that of each monotherapy drug and of the combination in patients with endometrial cancer and other solid tumors. Given the medical complexity of patients with aEC, this paper aims to characterize key adverse reactions (ARs) of the combination treatment and review management strategies, providing a guide for AR management to maximize anticancer benefits and minimize treatment discontinuation. Materials and methods. In Study-309/KEYNOTE-775, patients received lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously every 3 weeks) or chemotherapy (doxorubicin or paclitaxel). The incidence and median time to the first onset of ARs, dose modifications, and concomitant medications are described. Key ARs characterized include hypothyroidism, hypertension, fatigue, diarrhea, musculoskeletal disorders, nausea, decreased appetite, vomiting, stomatitis, weight decreased, proteinuria, and palmar-plantar erythrodysesthesia syndrome. Results. As expected, the most common any-grade key ARs included: hypothyroidism, hypertension, fatigue, diarrhea, and musculoskeletal disorders. Grades 3-4 key ARs with incidence ≥10% included: hypertension, fatigue, and weight decreased. Key ARs first occurred within approximately 3 months of treatment initiation. AR management strategies consistent with the prescribing information and the study protocol are discussed. Conclusion. Successful AR management strategies for lenvatinib plus pembrolizumab include education of the patient and entire treatment team, preventative measures and close monitoring, and judicious use of dose modifications and conc

Published
2023

38. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice

Author

Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., Makker V., Lorusso, D, Colombo, N, Herraez, A, Santin, A, Colomba, E, Miller, D, Fujiwara, K, Pignata, S, Baron-Hay, S, Ray-Coquard, I, Shapira-Frommer, R, Kim, Y, Mccormack, M, Massaad, R, Nguyen, A, Zhao, Q, Mckenzie, J, Prabhu, V, Makker, V, Lorusso D., Colombo N., Herraez A. C., Santin A. D., Colomba E., Miller D. S., Fujiwara K., Pignata S., Baron-Hay S. E., Ray-Coquard I. L., Shapira-Frommer R., Kim Y. M., McCormack M., Massaad R., Nguyen A. M., Zhao Q., McKenzie J., Prabhu V. S., and Makker V.

Abstract

Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase 3 Study 309/KEYNOTE-775. Health-related quality-of-life (HRQoL) is reported. Patients and Methods: Patients were randomly assigned to receive LEN+PEMBRO (n = 411; LEN 20 mg/day; PEMBRO 200 mg Q3W) or TPC (n = 416; doxorubicin 60 mg/m2 Q3W or paclitaxel 80 mg/m2 [weekly, 3 weeks on/1 week off]). Impact of treatment on HRQoL assessed by the global health status/quality of life (GHS/QoL) score of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) was a secondary objective; other scales of the Quality-of-Life Questionnaire (QLQ-C30), EORTC QLQ-Endometrial, 24 questions (EORTC QLQ-EN24), and EuroQoL 5 dimensions, 5 levels (EQ-5D-5L) were exploratory objectives. HRQoL was assessed on day 1 of each cycle. Completion/compliance, change from baseline, time to first and definitive deterioration were assessed. No multiplicity adjustments were applied for HRQoL endpoints. Results: The latest timepoint at which the predefined rates of completion (≥60%) and compliance (≥80%) were met was week 12. HRQoL at week 12 between treatment groups was generally similar. Time to first deterioration symptom scales favoured LEN+PEMBRO for QLQ-C30 dyspnoea, and QLQ-EN24 for poor body image, tingling/numbness, and hair loss; and TPC was favoured for QLQ-C30 pain, appetite loss, and diarrhoea, and QLQ-EN24 muscular pain. While the QLQ-C30 physical functional scale favoured TPC, other functional scales were generally similar between arms. Time to definitive deterioration favoured LEN+PEMBRO on most scales. Conclusion: HRQoL data from Study 309/KEYNOTE-775, with previously published efficacy and safety results, indicate that LEN+PEMBRO has an overall favourable benefit/risk profile versus TPC fo

Published
2023

39. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer

Author

Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., Rizzolo R., Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., and Rizzolo R.

Abstract

Late diagnosis and the lack of screening methods for early detection define high-grade serous ovarian cancer (HGSOC) as the gynecological malignancy with the highest mortality rate. In the work presented here, we investigated a retrospective and multicentric cohort of 250 archival Papanicolaou (Pap) test smears collected during routine gynecological screening. Samples were taken at different time points (from 1 month to 13.5 years before diagnosis) from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women. Genome instability was detected through low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA). CPA values of DNA extracted from Pap test samples from pre-HGSOC women were substantially higher than those in samples from healthy women. Consistently with the longitudinal analysis of clonal pathogenic TP53 mutations, this assay could detect HGSOC presence up to 9 years before diagnosis. This finding confirms the continual shedding of tumor cells from fimbriae toward the endocervical canal, suggesting a new path for the early diagnosis of HGSOC. We integrated the CPA score into the EVA (early ovarian cancer) test, the sensitivity of which was 75% (95% CI, 64.97 to 85.79), the specificity 96% (95% CI, 88.35 to 100.00), and the accuracy 81%. This proof-of-principle study indicates that the early diagnosis of HGSOC is feasible through the analysis of genomic alterations in DNA from endocervical smears.

Published
2023

41. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Author

Baert, T., Banerjee, S., Belaroussi, I., Blecharz, P., Bruchim, I., Cibula, D., Colombo, N., Concin, N., Davidson, B., Dashora, A., Devouassoux-Shisheboran, M., du Bois, A., Ferrero, A., Glasspool, R., González-Martin, A., Heinzelmann-Schwarz, V., Joly, F., Kim, J.W., Kridelka, F., Ledermann, J., Lorusso, D., Mahner, S., McCluggage, W.G., McNeish, I., Mikami, M., Mirza, M.R., Morice, P., Nicum, S., Olbrecht, S., O’Donnell, D.M., Pautier, P., Planchamp, F., Pignata, S., Querleu, D., Ray-Coquard, I., Rodolakis, A., Sehouli, J., Selcukbiricik, F., Sessa, C., Singh, N., Tan, D.S.P., Timmerman, D., Tognon, G., van der Velden, J., Vergote, I., Witteveen, P.O., and Zeimet, A.G.

Published
2019
Full Text
View/download PDF

42. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting

Author

Hackl, Monika, Van Eycken, Elizabeth, Henau, Kris, Dimitrova, Nadya, Sekerija, Mario, Dušek, Ladislav, Mägi, Margit, Malila, Nea, Leinonen, Maarit, Velten, Michel, Troussard, Xavier, Bouvier, Veronique, Guizard, Anne-Valérie, Bouvier, Anne-Marie, Arveux, Patrick, Maynadié, Marc, Woronoff, Anne-Sophie, Robaszkiewicz, Michel, Baldi, Isabelle, Monnereau, Alain, Tretarre, Brigitte, Colonna, Marc, Molinié, Florence, Bara, Simona, Schvartz, Claire, Lapôtre-Ledoux, Bénédicte, Grosclaude, Pascale, Stabenow, Roland, Luttmann, Sabine, Nennecke, Alice, Engel, Jutta, Schubert-Fritschle, Gabriele, Heidrich, Jan, Holleczek, Bernd, Jónasson, Jón Gunnlaugur, Clough-Gorr, Kerri, Comber, Harry, Mazzoleni, Guido, Giacomin, Adriano, Sardo, Antonella Sutera, Barchielli, Alessandro, Serraino, Diego, De Angelis, Roberta, Mallone, Sandra, Tavilla, Andrea, Pierannunzio, Daniela, Rossi, Silvia, Santaquilani, Mariano, Knijn, Arnold, Pannozzo, Fabio, Gennaro, Valerio, Benfatto, Lucia, Ricci, Paolo, Autelitano, Mariangela, Spagnoli, Gianbattista, Fusco, Mario, Usala, Mario, Vitale, Francesco, Michiara, Maria, Tumino, Rosario, Mangone, Lucia, Falcini, Fabio, Ferretti, Stefano, Filiberti, Rosa Angela, Marani, Enza, Iannelli, Arturo, Sensi, Flavio, Piffer, Silvano, Gentilini, Maria, Madeddu, Anselmo, Ziino, Antonio, Maspero, Sergio, Candela, Pina, Stracci, Fabrizio, Tagliabue, Giovanna, Rugge, Massimo, Trama, Annalisa, Gatta, Gemma, Botta, Laura, Capocaccia, Riccardo, Pildava, Santa, Smailyte, Giedre, Calleja, Neville, Johannesen, Tom Børge, Rachtan, Jadwiga, Góźdź, Stanisław, Błaszczyk, Jerzy, Kępska, Kamila, de Lacerda, Gonçalo Forjaz, José Bento, Maria, Miranda, Ana, Safaei Diba, Chakameh, Almar, Enrique, Larrañaga, Nerea, de Munain, Arantza Lopez, Torrella-Ramos, Ana, Díaz García, José María, Marcos-Gragera, Rafael, Josè Sanchez, Maria, Navarro, Carmen, Salmeron, Diego, Moreno-Iribas, Conchi, Galceran, Jaume, Carulla, Marià, Mousavi, Mohsen, Bouchardy, Christine, Ess, Silvia M., Bordoni, Andrea, Konzelmann, Isabelle, Rashbass, Jem, Gavin, Anna, Brewster, David H., Huws, Dyfed Wyn, Visser, Otto, Bielska-Lasota, Magdalena, Primic-Zakelj, Maja, Kunkler, Ian, Benhamou, Ellen, Ray-Coquard, I., Trama, AnnaLisa, Seckl, M.J., Fotopoulou, C., Pautier, P., Pignata, S., Kristensen, G., Mangili, G., Falconer, H., Massuger, L., Sehouli, J., Pujade-Lauraine, E., Lorusso, D., Amant, F., Rokkones, E., Vergote, I., and Ledermann, J.A.

Published
2019
Full Text
View/download PDF

43. 10P An adapted CGP-based model to interpret POLE mutations in endometrial cancer

Author

Trozzi, R., primary, Ottaviani, M., additional, Nero, C., additional, Duranti, S., additional, Camarda, F., additional, Marino, I., additional, Giacò, L., additional, De Marco, L., additional, Preziosi, A., additional, Minucci, A., additional, de Bonis, M., additional, Perrucci, A., additional, Onori, M.E., additional, Maneri, G., additional, Sillano, F., additional, Lorusso, D., additional, Fanfani, F., additional, Pasciuto, T., additional, Mozzetta, I., additional, and Scambia, G., additional

Published
2023
Full Text
View/download PDF

45. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

Author

Piccirillo, M.C., Scambia, G., Bologna, A., Signoriello, S., Vergote, I., Baumann, K., Lorusso, D., Murgia, V., Sorio, R., Ferrandina, G., Sacco, C., Cormio, G., Breda, E., Cinieri, S., Natale, D., Mangili, G., Pisano, C., Cecere, S.C., Di Napoli, M., Salutari, V., Raspagliesi, F., Arenare, L., Bergamini, A., Bryce, J., Daniele, G., Gallo, C., Pignata, S., and Perrone, F.

Published
2018
Full Text
View/download PDF

46. An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019–2020

Author

Pinkney T., Taylor H., Tong C., Schmitz N. -D., Morton D. G., Pinkney T. D., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y. E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E. L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N. Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Methodology, APH - Personalized Medicine, Pinkney, T, Taylor, H, Tong, C, Schmitz, N, Morton, D, Bhangu, A, Blackwell, S, Dardanov, D, Dulskas, A, Gallo, G, Glasbey, J, Keatley, J, Knowles, C, Li, Y, Mccourt, V, Minaya-Bravo, A, Neary, P, Nepogodiev, D, Pata, F, Pellino, G, Sivrikoz, E, van Ramshorst, G, Zmora, O, Perry, R, Magill, E, Abdalkoddus, M, Abelevich, A, Abraham, S, Abraham-Nordling, M, Adamina, M, Agalar, C, Agresta, F, Ahallat, M, Ahmad, N, Aiupov, R, Akca, O, Aleksic, A, Aleotti, F, Alias, D, Alonso, J, Alonso Goncalves, S, Alonso Martin, J, Alonso Poza, A, Alonso-Hernandez, N, Alos Company, R, Al-Saeedi, M, Alvarez-Laso, C, Alvarez-Gallego, M, Amanatidis, T, Americano, M, Amorim, E, Anandan, L, Anania, G, Ancans, G, Andreev, P, Andrejevic, P, Antonacci, N, Anwer, M, Aonzo, P, Arencibia, B, Argeny, S, Arieli, H, Arnold, S, Ashraf, M, Aslam, M, Atanasov, B, Atif, M, Atladottir, J, Avital, S, Awny, S, Aytac, B, Azahr, N, Aznar-Puig, S, Bailey, S, Balalis, D, Baldi, C, Baldonedo, R, Balducci, G, Balestra, F, Balestri, R, Balfour, A, Baloyiannis, I, Banky, B, Baral, J, Baranyai, Z, Barbashinov, N, Bargallo, J, Barisic, G, Barugola, G, Batashki, I, Battersby, N, Belev, N, Belli, A, Beltran de Heredia, J, Bemelman, W, Benavides Buleje, J, Benckert, A, Bernal-Sprekelsen, J, Bertocchi, E, Beuran, M, Bhan, C, Bianco, F, Bilali, S, Bilali, V, Bintintan, V, Birindelli, A, Birsan, T, Blanco Antona, F, Blas, J, Blasco-Segura, T, Blom, R, Bocchetti, T, Boerma, E, Bogdan, M, Boland, M, Bomans, B, Borda, N, Bowen, M, Bradulskis, S, Branagan, G, Brankovic, B, Brenna, M, Brewer, H, Broadhurst, J, Bronder, C, Brouwer, R, Buccianti, P, Buchs, N, Buchwald, P, Bugatti, A, Bui, A, Burcos, T, Buskens, C, Bustamante, C, Caceres, N, Cagigas Fernandez, C, Calero-Lillo, A, Camps, I, Canda, A, Caravaca-Garcia, I, Carballo, F, Carcoforo, P, Carlander, J, Carlos, S, Caro, A, Carpelan, A, Carrasco Prats, M, Carrillo Lopez, M, Carvello, M, Casal, E, Casoni Pattacini, G, Castellvi Valls, J, Castillo Diego, J, Cavallesco, G, Cavenaile, V, Cayetano, L, Ceccotti, A, Cervera-Aldama, J, Chabok, A, Chafai, N, Chandrasinghe, P, Chandratreya, N, Chaudhri, S, Chaudhry, Z, Cherdancev, D, Chernov, A, Chevallay, M, Chirletti, P, Chouillard, E, Chouliaras, C, Chowdri, N, Cillo, M, Cini, C, Ciubotaru, C, Ciuce, C, Claeys, D, Cocorullo, G, Codina-Cazador, A, Colak, E, Coletta, D, Colombo, F, Copaescu, C, Corte Real, J, Corver, M, Cosic, J, Costa, S, Costa Pereira, J, Costa Pereira, C, Costa-Navarro, D, Cotte, E, Cracco, N, Cristian, D, Cuadrado, M, Cuk, V, Cunha, M, Cunha, J, Curinga, R, Curletti, G, Curtis, N, Dabic, D, Dainius, E, D'Alessandro, A, Daniels, I, Darvin, V, Dauser, B, David, G, Davidova, O, Davies, E, de Andres Asenjo, B, De franciscis, S, de Graaf, E, De la Portilla, F, De Luca, E, De Nisco, C, De Toma, G, Defoort, B, Den Boer, F, Di Candido, F, Di Saverio, S, Diaz Pavon, J, Dieguez Fernandez, B, Diez-Alonso, M, Dimitrijevic, I, Dindelegan, G, Djuric, M, Domingos, H, Doornebosch, P, Dos Santos, M, Drami, I, Dudarovaska, H, Dusek, T, Dzhumabaev, H, Eden, Y, Egenvall, M, Eismiontas, V, El Sorogy, M, Elgeidie, A, Elhemaly, M, El-Hussuna, A, Ellul, S, Elmore, U, Elnakeeb, A, Elrefai, M, Emile, S, Enrriquez-Navascues, J, Epstein, J, Escartin, J, Escola, D, Escuder, J, Espin, E, Espina, B, Estefania, D, Etienne, J, Fabbri, S, Falato, A, Fares, R, Farina, P, Farkasova, M, Farres, R, Fasolini, F, Fatayer, T, Febles, G, Feliu, F, Feo, C, Feoktistov, D, Fernandez, F, Fernandez Isart, M, Fernando, J, Ferreira, G, Ferrer, R, Ferreras Garcia, C, Ferri, M, Figueiredo, N, Finotti, E, Fitzgerald, J, Flateh Backe, I, Flor-Lorente, B, Forero-Torres, A, Foschi, D, Francart, D, Francois, Y, Frasson, M, Freil-Lanter, C, Frois Borges, M, Fuzun, M, Gala, T, Galleano, R, Galvez, P, Galvez Saldana, A, Gamundi Cuesta, M, Garcia Cabrera, A, Garcia Egea, J, Garcia Olmo, D, Garcia-Gonzalez, J, Garcia-Granero, A, Garcia-Granero, E, Garcia-Septiem, J, Gardea, A, Garipov, M, Gefen, R, Geraghty, A, Gerkis, S, Germanos, S, Ghaffari, S, Ghilles, E, Gianotti, L, Gil Santos, M, Gilsanz Martin, C, Gingert, C, Gklavas, A, Glehen, O, Golda, T, Gomez, N, Gomez, R, Gomez Ruiz, M, Gonzalez Santin, V, Graham, B, Grainger, J, Grama, F, Gregoir, T, Gregori, M, Grolich, T, Grosek, J, Guadalajara, H, Guckenheimer, S, Guevara, J, Gulotta, G, Gupta, S, Gurevich, N, Gurjar, S, Haapaniemi, S, Hahnloser, D, Hamad, Y, Hamid, M, Hanly, A, Harris, G, Harsanyi, L, Hartig, N, Hawkin, P, Henriques, P, Herbst, F, Hermann, N, Hernandez Garcia, M, Hoch, J, Hrora, A, Huhtinen, H, Iarumov, N, Ilkanich, A, Insua, C, Ioannidis, P, Iqbal, M, Iqbal, A, Isik, A, Ismaiel, M, Ivlev, D, Jadhav, V, Jareno, S, Jehaes, C, Jimenez, V, Jimenez-Toscano, M, Jimenez-Miramon, J, Jimenez-Rodriguez, R, Jonsson, T, Jotautas, V, Julia, D, Juloski, J, Jung, B, Kala, Z, Kalayci, M, Kara, Y, Karachun, A, Karagul, S, Karvonen, J, Katorkin, S, Katsoulis, I, Katsounis, D, Kaubrys, M, Kaul, N, Kefalou, E, Keijzers, M, Kelly, M, Kenic, M, Kennelly, R, Khan, J, Khan, M, Kho, H, Kinas, V, Knight, J, Kocian, P, Koeter, T, Kokobelyan, A, Konsten, J, Koolen, L, Kosir, J, Kostic, I, Krdzic, I, Kreisler Moreno, E, Krivokapic, Z, Krstev, P, Krsul, D, Kumarasinghe, N, La Torre, F, Labarga, F, Ladra, M, Lage Laredo, A, Lahodzich, N, Lai, C, Lakkis, Z, Lal, R, Lamas, S, Lang, T, Latkauskas, T, Lawes, D, Lazar, G, Lebedev, K, Lebedeva, M, Lefevre, J, Lekic Vitlov, V, Lemma, M, Leo, C, Leon, C, Leventoglu, S, Levy, B, Li, L, Licari, L, Lizdenis, P, Loftas, P, Longhi, M, Longstaff, L, Lopez Dominguez, J, Lopez-Lara, M, Lora, P, Lorenzon, L, Lorusso, D, Lozev, I, Lozoya Trujillo, R, Lukic, D, Lunins, R, Luzan, R, Luzzi, A, Maderuelo, V, Madsboll, T, Mahotin, D, Majbar, M, Makhmudov, A, Malik, K, Maly, O, Mamaloudis, I, Mamedli, Z, Manatakis, D, Mandi, D, Mangell, P, Marharint, T, Mariani, N, Maric, B, Marimuthu, K, Marinello, F, Marino, F, Markiewicz, S, Markovic, V, Marom, G, Maroni, N, Maroulis, I, Marsanic, P, Marsman, H, Martens, M, Marti, M, Martinek, L, Martinez, S, Martinez, D, Martinez Manzano, A, Martins, R, Maslyankov, S, Mcardle, K, Mcdermott, F, Mege, D, Mehraj, A, Mehta, A, Mendrila, D, Menendez, P, Mercantini, P, Metwally, I, Mikalauskas, S, Millan, M, Mingoli, A, Mirshekar-Syahkal, B, Moggia, E, Mohan, S, Moller, P, Mompart Garcia, S, Monami, B, Moniz Pereira, P, Montroni, I, Morel, P, Moshev, B, Mostovoy, E, Mothe, S, Mukhtar, H, Muller, P, Munch, S, Munoz Camarena, J, Munoz-Collado, S, Muratore, A, Muscara, F, Muysoms, F, Myrelid, P, N. Lah, N, Nail, S, Narayanan, A, Nastos, K, Negoi, I, Nesbakken, A, Nestler, G, Nestorovic, M, Nesytykh, A, Newton, K, Ng, Y, Ngu, J, Nguyen, B, Nijs, Y, Nikberg, M, Nimmersgern, T, Nogues, E, Norcic, G, Nutautiene, V, Nygren, J, O'Brien, J, Ochogavia Segui, A, O'Kelly, J, Oliveira-Cunha, M, Omar, W, Omar, G, Onishchenko, S, Onody, P, Opocher, E, Orhalmi, J, Oshowo, A, Otero, J, Ozgen, U, Pace, K, Padin, H, Papaconstantinou, I, Papadopoulos, A, Papadopoulos, G, Papandrea, M, Paral, J, Parc, Y, Paredes, J, Parmar, M, Parra Banos, P, Parray, F, Pascual Damieta, M, Pascual Miguelanez, I, Passot, G, Pastor, C, Paszt, A, Patel, P, Paterson, H, Patron Uriburu, J, Paulos, A, Pavlov, V, Pcolkins, A, Pecic, V, Pena Ros, E, Penkov, R, Pera Roman, M, Perunicic, V, Pery, R, Petrovic, D, Pezzolla, F, Photi, E, Pikarsky, A, Piramanayagam, B, Pisani Ceretti, A, Planellas, P, Platt, E, Pletinckx, P, Podda, M, Poskus, T, Poskus, E, Pozdnyakov, A, Pravosudov, I, Previsic, A, Prieto, D, Prochazka, V, Prodan, A, Proud, D, Psaila, J, Psaras, G, Pulighe, F, Pullig, F, Qureshi, M, Rachadell, J, Radovanovic, Z, Radovanovic, D, Raguan, B, Rahman, M, Raiss, M, Ramirez Faraco, M, Ramos, J, Ramos-Prada, J, Rantala, A, Rao, M, Rasulov, A, Ratnatunga, K, Raymond, T, Refky, B, Reggiani, L, Regusci, L, Reyes Diaz, M, Richardson, J, Richiteanu, G, Rios, A, Ris, F, Rodriguez Garcia, P, Roffi, N, Romairone, E, Romano, G, Romero, I, Romero de Diego, A, Romero-Simo, M, Roque, C, Rosati, R, Rossi, B, Rossi, E, Rossini, R, Ruano, A, Rubbini, M, Rubio-Perez, I, Ruffo, G, Ruiz, H, Ruiz Carmona, M, Ryska, O, Sabia, D, Sacchi, M, Sacco, R, Sakr, A, Saladzinskas, Z, Salamone, G, Salomon, M, Salvans Ruiz, S, Sammarco, G, Sampietro, G, Samsonov, D, Samsonyuk, V, Sanchez, J, Sanchez Romero, A, Sanchez-Guillen, L, Santak, G, Santamaria-Olabarrieta, M, Santos, J, Saraceno, F, Saralegui, Y, Sarici, I, Savino, G, Scabini, S, Schafli, J, Schiltz, B, Schofield, A, Schon, M, Scurtu, R, Segalini, E, Segelman, J, Segura-Sampedro, J, Seicean, R, Sekulic, A, Selniahina, L, Seretis, F, Serrano Paz, P, Shaikh, I, Shalaby, M, Shams, N, Sharma, A, Sharma, G, Shukla, A, Shussman, N, Shweejawee, Z, Sielezneff, I, Sigurdsson, H, Sileri, P, Silva, M, Simcikas, D, Simoes, J, Simonka, Z, Singh, B, Sivins, A, Skroubis, G, Skull, A, Slavchev, M, Slavin, M, Smart, N, Smart, C, Smart, P, Smedh, K, Smolarek, S, Sokmen, S, Sokolov, M, Solana Bueno, A, Solar, L, Sorrentino, L, Sotona, O, Spacca, D, Spinelli, A, Stanojevic, G, Stearns, A, Stefan, S, Stift, A, Stijns, J, Stoyanov, V, Straarup, D, Strupas, K, Stubbs, B, Subocius, A, Sudlow, A, Suero, C, Sungurtekin, U, Svagzdys, S, Syk, I, Tamelis, A, Tamhane, R, Tamini, N, Tamosiunas, A, Tanis, P, Tarasov, N, Tate, S, Tennakoon, A, Teo, N, Terzi, C, Tezas, S, Thabet, W, Tham, J, Thavanesan, N, Theodosopoulos, T, Thomas, W, Tiret, E, Tiselius, C, Todorov, G, Tomazic, A, Tomulescu, V, Torkington, J, Totis, M, Trostchansky, I, Truan, N, Tulchinsky, H, Tutino, R, Tzivanakis, A, Tzovaras, G, Ugolini, G, Unger, L, Upanishad, I, Urbani, L, Uth Ovesen, A, Vaizey, C, Vallribera, F, Valsdottir, E, Valverde, I, Valverde-Sintas, J, Van Belle, K, Van Cleven, S, van Hagen, P, van Loon, Y, van Ruler, O, Van Wijck, K, Varabei, A, Varcada, M, Varpe, P, Vartic, M, Velchuru, V, Vencius, J, Venskutonis, D, Vercher, D, Vermaas, M, Vertruyen, M, Verza, L, Vescio, G, Vezakis, A, Vieira, P, Vignali, A, Vigorita, V, Vila Tura, M, Vinson-Bonnet, B, Viso Pons, L, Voloshin, S, Voronin, Y, Vukusic, L, Wang, X, Wang, J, Wani, R, Warusavitarne, J, Wasserberg, N, Weerts, J, Weiss, D, Weizman, A, Westerduin, E, Wheat, J, White, I, Wik, T, Wilson, J, Winter, D, Wolthuis, A, Wong, M, Yahia, S, Yamamoto, T, Yanishev, A, Yao, C, Yildiz, A, Yuksel, O, Zain, Z, Zakaria, A, Zakaria, Z, Zampitis, N, Zarand, A, Zarco-Pleguezuelos, A, Zattoni, D, Zelic, M, Zeromskas, P, Zhuravlev, A, Zimmerman, D, Zuhdy, M, Zukanovic, G, Pinkney T.D., Taylor H., Tong C., Schmitz N.-D., Morton D.G., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y.E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E.L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N.Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Pinkney, T. D., Taylor, H., Tong, C., Schmitz, N. -D., Morton, D. G., Bhangu, A., Blackwell, S., Dardanov, D., Dulskas, A., Gallo, G., Glasbey, J., Keatley, J., Knowles, C., Li, Y. E., Mccourt, V., Minaya-Bravo, A., Neary, P., Nepogodiev, D., Pata, F., Pellino, G., Sivrikoz, E., van Ramshorst, G., Zmora, O., Perry, R., Magill, E. L., Abdalkoddus, M., Abelevich, A., Abraham, S., Abraham-Nordling, M., Adamina, M., Agalar, C., Agresta, F., Ahallat, M., Ahmad, N., Aiupov, R., Akca, O., Aleksic, A., Aleotti, F., Alias, D., Alonso, J., Alonso Goncalves, S., Alonso Martin, J., Alonso Poza, A., Alonso-Hernandez, N., Alos Company, R., Al-Saeedi, M., Alvarez-Laso, C., Alvarez-Gallego, M., Amanatidis, T., Americano, M., Amorim, E., Anandan, L., Anania, G., Ancans, G., Andreev, P., Andrejevic, P., Antonacci, N., Anwer, M., Aonzo, P., Arencibia, B., Argeny, S., Arieli, H., Arnold, S., Ashraf, M., Aslam, M., Atanasov, B., Atif, M., Atladottir, J., Avital, S., Awny, S., Aytac, B., Azahr, N., Aznar-Puig, S., Bailey, S., Balalis, D., Baldi, C., Baldonedo, R., Balducci, G., Balestra, F., Balestri, R., Balfour, A., Baloyiannis, I., Banky, B., Baral, J., Baranyai, Z., Barbashinov, N., Bargallo, J., Barisic, G., Barugola, G., Batashki, I., Battersby, N., Belev, N., Belli, A., Beltran de Heredia, J., Bemelman, W., Benavides Buleje, J., Benckert, A., Bernal-Sprekelsen, J., Bertocchi, E., Beuran, M., Bhan, C., Bianco, F., Bilali, S., Bilali, V., Bintintan, V., Birindelli, A., Birsan, T., Blanco Antona, F., Blas, J., Blasco-Segura, T., Blom, R., Bocchetti, T., Boerma, E., Bogdan, M., Boland, M., Bomans, B., Borda, N., Bowen, M., Bradulskis, S., Branagan, G., Brankovic, B., Brenna, M., Brewer, H., Broadhurst, J., Bronder, C., Brouwer, R., Buccianti, P., Buchs, N., Buchwald, P., Bugatti, A., Bui, A., Burcos, T., Buskens, C., Bustamante, C., Caceres, N., Cagigas Fernandez, C., Calero-Lillo, A., Camps, I., Canda, A., Caravaca-Garcia, I., Carballo, F., Carcoforo, P., Carlander, J., Carlos, S., Caro, A., Carpelan, A., Carrasco Prats, M., Carrillo Lopez, M., Carvello, M., Casal, E., Casoni Pattacini, G., Castellvi Valls, J., Castillo Diego, J., Cavallesco, G., Cavenaile, V., Cayetano, L., Ceccotti, A., Cervera-Aldama, J., Chabok, A., Chafai, N., Chandrasinghe, P., Chandratreya, N., Chaudhri, S., Chaudhry, Z., Cherdancev, D., Chernov, A., Chevallay, M., Chirletti, P., Chouillard, E., Chouliaras, C., Chowdri, N., Cillo, M., Cini, C., Ciubotaru, C., Ciuce, C., Claeys, D., Cocorullo, G., Codina-Cazador, A., Colak, E., Coletta, D., Colombo, F., Copaescu, C., Corte Real, J., Corver, M., Cosic, J., Costa, S., Costa Pereira, J., Costa Pereira, C., Costa-Navarro, D., Cotte, E., Cracco, N., Cristian, D., Cuadrado, M., Cuk, V., Cunha, M., Cunha, J., Curinga, R., Curletti, G., Curtis, N., Dabic, D., Dainius, E., D'Alessandro, A., Daniels, I., Darvin, V., Dauser, B., David, G., Davidova, O., Davies, E., de Andres Asenjo, B., De franciscis, S., de Graaf, E., De la Portilla, F., De Luca, E., De Nisco, C., De Toma, G., Defoort, B., Den Boer, F., Di Candido, F., Di Saverio, S., Diaz Pavon, J., Dieguez Fernandez, B., Diez-Alonso, M., Dimitrijevic, I., Dindelegan, G., Djuric, M., Domingos, H., Doornebosch, P., Dos Santos, M., Drami, I., Dudarovaska, H., Dusek, T., Dzhumabaev, H., Eden, Y., Egenvall, M., Eismiontas, V., El Sorogy, M., Elgeidie, A., Elhemaly, M., El-Hussuna, A., Ellul, S., Elmore, U., Elnakeeb, A., Elrefai, M., Emile, S., Enrriquez-Navascues, J., Epstein, J., Escartin, J., Escola, D., Escuder, J., Espin, E., Espina, B., Estefania, D., Etienne, J., Fabbri, S., Falato, A., Fares, R., Farina, P., Farkasova, M., Farres, R., Fasolini, F., Fatayer, T., Febles, G., Feliu, F., Feo, C., Feoktistov, D., Fernandez, F., Fernandez Isart, M., Fernando, J., Ferreira, G., Ferrer, R., Ferreras Garcia, C., Ferri, M., Figueiredo, N., Finotti, E., Fitzgerald, J., Flateh Backe, I., Flor-Lorente, B., Forero-Torres, A., Foschi, D., Francart, D., Francois, Y., Frasson, M., Freil-Lanter, C., Frois Borges, M., Fuzun, M., Gala, T., Galleano, R., Galvez, P., Galvez Saldana, A., Gamundi Cuesta, M., Garcia Cabrera, A., Garcia Egea, J., Garcia Olmo, D., Garcia-Gonzalez, J., Garcia-Granero, A., Garcia-Granero, E., Garcia-Septiem, J., Gardea, A., Garipov, M., Gefen, R., Geraghty, A., Gerkis, S., Germanos, S., Ghaffari, S., Ghilles, E., Gianotti, L., Gil Santos, M., Gilsanz Martin, C., Gingert, C., Gklavas, A., Glehen, O., Golda, T., Gomez, N., Gomez, R., Gomez Ruiz, M., Gonzalez Santin, V., Graham, B., Grainger, J., Grama, F., Gregoir, T., Gregori, M., Grolich, T., Grosek, J., Guadalajara, H., Guckenheimer, S., Guevara, J., Gulotta, G., Gupta, S., Gurevich, N., Gurjar, S., Haapaniemi, S., Hahnloser, D., Hamad, Y., Hamid, M., Hanly, A., Harris, G., Harsanyi, L., Hartig, N., Hawkin, P., Henriques, P., Herbst, F., Hermann, N., Hernandez Garcia, M., Hoch, J., Hrora, A., Huhtinen, H., Iarumov, N., Ilkanich, A., Insua, C., Ioannidis, P., Iqbal, M., Iqbal, A., Isik, A., Ismaiel, M., Ivlev, D., Jadhav, V., Jareno, S., Jehaes, C., Jimenez, V., Jimenez-Toscano, M., Jimenez-Miramon, J., Jimenez-Rodriguez, R., Jonsson, T., Jotautas, V., Julia, D., Juloski, J., Jung, B., Kala, Z., Kalayci, M., Kara, Y., Karachun, A., Karagul, S., Karvonen, J., Katorkin, S., Katsoulis, I., Katsounis, D., Kaubrys, M., Kaul, N., Kefalou, E., Keijzers, M., Kelly, M., Kenic, M., Kennelly, R., Khan, J., Khan, M., Kho, H., Kinas, V., Knight, J., Kocian, P., Koeter, T., Kokobelyan, A., Konsten, J., Koolen, L., Kosir, J., Kostic, I., Krdzic, I., Kreisler Moreno, E., Krivokapic, Z., Krstev, P., Krsul, D., Kumarasinghe, N., La Torre, F., Labarga, F., Ladra, M., Lage Laredo, A., Lahodzich, N., Lai, C., Lakkis, Z., Lal, R., Lamas, S., Lang, T., Latkauskas, T., Lawes, D., Lazar, G., Lebedev, K., Lebedeva, M., Lefevre, J., Lekic Vitlov, V., Lemma, M., Leo, C., Leon, C., Leventoglu, S., Levy, B., Li, L., Licari, L., Lizdenis, P., Loftas, P., Longhi, M., Longstaff, L., Lopez Dominguez, J., Lopez-Lara, M., Lora, P., Lorenzon, L., Lorusso, D., Lozev, I., Lozoya Trujillo, R., Lukic, D., Lunins, R., Luzan, R., Luzzi, A., Maderuelo, V., Madsboll, T., Mahotin, D., Majbar, M., Makhmudov, A., Malik, K., Maly, O., Mamaloudis, I., Mamedli, Z., Manatakis, D., Mandi, D., Mangell, P., Marharint, T., Mariani, N., Maric, B., Marimuthu, K., Marinello, F., Marino, F., Markiewicz, S., Markovic, V., Marom, G., Maroni, N., Maroulis, I., Marsanic, P., Marsman, H., Martens, M., Marti, M., Martinek, L., Martinez, S., Martinez, D., Martinez Manzano, A., Martins, R., Maslyankov, S., Mcardle, K., Mcdermott, F., Mege, D., Mehraj, A., Mehta, A., Mendrila, D., Menendez, P., Mercantini, P., Metwally, I., Mikalauskas, S., Millan, M., Mingoli, A., Mirshekar-Syahkal, B., Moggia, E., Mohan, S., Moller, P., Mompart Garcia, S., Monami, B., Moniz Pereira, P., Montroni, I., Morel, P., Moshev, B., Mostovoy, E., Mothe, S., Mukhtar, H., Muller, P., Munch, S., Munoz Camarena, J., Munoz-Collado, S., Muratore, A., Muscara, F., Muysoms, F., Myrelid, P., N. Lah, N., Nail, S., Narayanan, A., Nastos, K., Negoi, I., Nesbakken, A., Nestler, G., Nestorovic, M., Nesytykh, A., Newton, K., Ng, Y., Ngu, J., Nguyen, B., Nijs, Y., Nikberg, M., Nimmersgern, T., Nogues, E., Norcic, G., Nutautiene, V., Nygren, J., O'Brien, J., Ochogavia Segui, A., O'Kelly, J., Oliveira-Cunha, M., Omar, W., Omar, G., Onishchenko, S., Onody, P., Opocher, E., Orhalmi, J., Oshowo, A., Otero, J., Ozgen, U., Pace, K., Padin, H., Papaconstantinou, I., Papadopoulos, A., Papadopoulos, G., Papandrea, M., Paral, J., Parc, Y., Paredes, J., Parmar, M., Parra Banos, P., Parray, F., Pascual Damieta, M., Pascual Miguelanez, I., Passot, G., Pastor, C., Paszt, A., Patel, P., Paterson, H., Patron Uriburu, J., Paulos, A., Pavlov, V., Pcolkins, A., Pecic, V., Pena Ros, E., Penkov, R., Pera Roman, M., Perunicic, V., Pery, R., Petrovic, D., Pezzolla, F., Photi, E., Pikarsky, A., Piramanayagam, B., Pisani Ceretti, A., Planellas, P., Platt, E., Pletinckx, P., Podda, M., Poskus, T., Poskus, E., Pozdnyakov, A., Pravosudov, I., Previsic, A., Prieto, D., Prochazka, V., Prodan, A., Proud, D., Psaila, J., Psaras, G., Pulighe, F., Pullig, F., Qureshi, M., Rachadell, J., Radovanovic, Z., Radovanovic, D., Raguan, B., Rahman, M., Raiss, M., Ramirez Faraco, M., Ramos, J., Ramos-Prada, J., Rantala, A., Rao, M., Rasulov, A., Ratnatunga, K., Raymond, T., Refky, B., Reggiani, L., Regusci, L., Reyes Diaz, M., Richardson, J., Richiteanu, G., Rios, A., Ris, F., Rodriguez Garcia, P., Roffi, N., Romairone, E., Romano, G., Romero, I., Romero de Diego, A., Romero-Simo, M., Roque, C., Rosati, R., Rossi, B., Rossi, E., Rossini, R., Ruano, A., Rubbini, M., Rubio-Perez, I., Ruffo, G., Ruiz, H., Ruiz Carmona, M., Ryska, O., Sabia, D., Sacchi, M., Sacco, R., Sakr, A., Saladzinskas, Z., Salamone, G., Salomon, M., Salvans Ruiz, S., Sammarco, G., Sampietro, G., Samsonov, D., Samsonyuk, V., Sanchez, J., Sanchez Romero, A., Sanchez-Guillen, L., Santak, G., Santamaria-Olabarrieta, M., Santos, J., Saraceno, F., Saralegui, Y., Sarici, I., Savino, G., Scabini, S., Schafli, J., Schiltz, B., Schofield, A., Schon, M., Scurtu, R., Segalini, E., Segelman, J., Segura-Sampedro, J., Seicean, R., Sekulic, A., Selniahina, L., Seretis, F., Serrano Paz, P., Shaikh, I., Shalaby, M., Shams, N., Sharma, A., Sharma, G., Shukla, A., Shussman, N., Shweejawee, Z., Sielezneff, I., Sigurdsson, H., Sileri, P., Silva, M., Simcikas, D., Simoes, J., Simonka, Z., Singh, B., Sivins, A., Skroubis, G., Skull, A., Slavchev, M., Slavin, M., Smart, N., Smart, C., Smart, P., Smedh, K., Smolarek, S., Sokmen, S., Sokolov, M., Solana Bueno, A., Solar, L., Sorrentino, L., Sotona, O., Spacca, D., Spinelli, A., Stanojevic, G., Stearns, A., Stefan, S., Stift, A., Stijns, J., Stoyanov, V., Straarup, D., Strupas, K., Stubbs, B., Subocius, A., Sudlow, A., Suero, C., Sungurtekin, U., Svagzdys, S., Syk, I., Tamelis, A., Tamhane, R., Tamini, N., Tamosiunas, A., Tanis, P., Tarasov, N., Tate, S., Tennakoon, A., Teo, N., Terzi, C., Tezas, S., Thabet, W., Tham, J., Thavanesan, N., Theodosopoulos, T., Thomas, W., Tiret, E., Tiselius, C., Todorov, G., Tomazic, A., Tomulescu, V., Torkington, J., Totis, M., Trostchansky, I., Truan, N., Tulchinsky, H., Tutino, R., Tzivanakis, A., Tzovaras, G., Ugolini, G., Unger, L., Upanishad, I., Urbani, L., Uth Ovesen, A., Vaizey, C., Vallribera, F., Valsdottir, E., Valverde, I., Valverde-Sintas, J., Van Belle, K., Van Cleven, S., van Hagen, P., van Loon, Y., van Ruler, O., Van Wijck, K., Varabei, A., Varcada, M., Varpe, P., Vartic, M., Velchuru, V., Vencius, J., Venskutonis, D., Vercher, D., Vermaas, M., Vertruyen, M., Verza, L., Vescio, G., Vezakis, A., Vieira, P., Vignali, A., Vigorita, V., Vila Tura, M., Vinson-Bonnet, B., Viso Pons, L., Voloshin, S., Voronin, Y., Vukusic, L., Wang, X., Wang, J., Wani, R., Warusavitarne, J., Wasserberg, N., Weerts, J., Weiss, D., Weizman, A., Westerduin, E., Wheat, J., White, I., Wik, T., Wilson, J., Winter, D., Wolthuis, A., Wong, M., Yahia, S., Yamamoto, T., Yanishev, A., Yao, C., Yildiz, A., Yuksel, O., Zain, Z., Zakaria, A., Zakaria, Z., Zampitis, N., Zarand, A., Zarco-Pleguezuelos, A., Zattoni, D., Zelic, M., Zeromskas, P., Zhuravlev, A., Zimmerman, D., Zuhdy, M., and Zukanovic, G.

Subjects
medicine.medical_specialty, Prehabilitation, medicine.medical_treatment, MEDLINE, Colorectal Neoplasm, Perioperative Care, NO, medicine, Humans, 03.02. Klinikai orvostan, Perioperative Optimisation, Enhanced recovery after surgery, Digestive System Surgical Procedures, LS7_4, Enhanced Recovery After Surgery (ERAS), business.industry, Gastroenterology, Digestive System Surgical Procedure, Guideline, Colorectal surgery, Surgery, Family medicine, Perioperative care, Nasogastric intubation, Preoperative fasting, Colorectal Neoplasms, Enhanced Recovery After Surgery, business, Colorectal Surgery, Human
Abstract

Aim The Enhanced Recovery After Surgery (ERAS® ) Society guidelines aim to standardise perioperative care in colorectal surgery via 25 principles. We aimed to assess the variation in uptake of these principles across an international network of colorectal units. Method An online survey was circulated amongst European Society of Coloproctology members in 2019/20. For each ERAS® principle, respondents were asked to score how frequently the principle was implemented in their hospital, from 1 ('rarely') to 4 ('always'). Respondents were also asked to recall whether practice had changed since 2017. Subgroup analyses based on hospital characteristics were conducted. Results Of hospitals approached, 58% responded to the survey (195/335), with 296 individual responses (multiple responses were received from some hospitals). The majority were European (163/195 [83.6%]). Overall, respondents indicated they 'most often' or 'always' adhered to most individual ERAS® principles (18/25 [72%]). Variability in uptake of principles was reported, with universal uptake of some principles (e.g., prophylactic antibiotics; early mobilisation) and inconsistency from 'rarely' to 'always' in others (e.g., no nasogastric intubation; no preoperative fasting and carbohydrate drinks). In alignment with 2018 ERAS® guideline updates, adherence to principles for prehabilitation, managing anaemia, and postoperative nutrition appears to have increased since 2017. Conclusions Uptake of ERAS® principles varied across hospitals, and not all 25 principles were equally adhered to. Whilst some principles exhibited a high level of acceptance, others had a wide variability in uptake indicative of controversy or barriers to uptake. Further research into specific principles is required to improve ERAS® implementation.

Published
2021

47. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy

Author

Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, and Raspagliesi F

Subjects
Olaparib, Ovarian cancer, PARP inhibitors, Homologous Recombination Deficiency, BRCA mutation, Therapeutics. Pharmacology, RM1-950
Abstract

Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani, Francesco Raspagliesi Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy Abstract: Epithelial ovarian cancer is the sixth most common cancer among women worldwide and the first cause of death among gynecological malignancies. Most of the patients present recurrent disease and unfortunately cannot be cured. The unsatisfactory results obtained with salvage chemotherapy have elicited investigators to search for novel biological agents capable of achieving a better control of the disease. In the setting of homologous recombination deficiency, the DNA errors that occur cannot be accurately repaired, and the treatment with poly(ADP-ribose) polymerase (PARP) inhibition results in definitive cell death in a process called synthetic lethality. As a result of two positive clinical trials, Olaparib was approved in 2014 by U.S. Food and Drug Administration and European Medicines Agency as the first-in-class PARP inhibitor. Olaparib is effective and well tolerated in homologous recombination deficient patients. Several studies with Olaparib have been conducted in the recurrent setting either as maintenance in platinum-responsive patients or as a single agent. Ongoing trials are focused on the use of olaparib as maintenance in the first-line ovarian cancer setting alone or in combination with antiangiogenic agents. Future perspectives will probably investigate the association of olaparib with novel agents as check-point inhibitors and PI3K-AKT inhibitors. The PARP inhibitor era is just at the beginning. Keywords: olaparib, ovarian cancer, PARP inhibitors, homologous recombination deficiency, BRCA mutation

Published
2018

48. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, and Ledermann, Jonathan A

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results